Tirzepatide
Also known as: LY3298176
Quick summary
A single peptide that activates both the GIP and GLP-1 receptors and is dosed once a week. Research focus: dual GIP/GLP-1 agonism, body-weight regulation and insulin sensitivity. This page leads with SRP's low-and-slow starting dose.
Overview
A single peptide that activates both the GIP and GLP-1 receptors and is dosed once a week. It has a large body of clinical-trial data on weight and glucose outcomes.
Looking for research material? Simple Research Peptides lists TIRZ-GLP3 (Tirzepatide) 10 mg Research Vial for laboratory research use.
Mechanism
A single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, with a stronger pull toward GIP. A fatty-acid side chain that binds albumin allows once-weekly dosing in trials.
Research areas
- dual GIP/GLP-1 agonism
- body-weight regulation
- insulin sensitivity
Storage & reconstitution
Typically supplied as a lyophilized powder; keep sealed vials cold (refrigerated short term, frozen for long-term holding) and away from light. Laboratories commonly reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, and keep the solution refrigerated, using it within a few weeks.
Recommended starting dose (low and slow)
| Starting dose | Trial-style schedule: 2.5 mg once weekly for 4 weeks, subcutaneous. Trial doses were pharmaceutical product, not research vials. |
|---|---|
| Frequency | Once weekly (every 7 days). Half-life about 5 days. |
| Reconstitution | Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL (2.5 mg = 0.5 mL = 50 units). Refrigerate 2-8 °C, protect from light, use within ~28 days. |
Trial schedule: 2.5 mg once weekly SC for 4 weeks, then +2.5 mg steps at >=4-week intervals toward 5, 10 or 15 mg weekly. Half-life ~5 days. Trial doses were of the pharmaceutical product.
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Highest dose in the schedule: 15 mg once weekly. |
|---|---|
| Step-up schedules reported | Increase by 2.5 mg steps, no faster than every 4 weeks, toward 5, 10 or 15 mg weekly. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: About 5 days.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Tirzepatide studied for?
In research it is studied for dual GIP/GLP-1 agonism, body-weight regulation and insulin sensitivity. A single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, with a stronger pull toward GIP.
How is Tirzepatide given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026